Does the Type of Iron Infusion Affect Phosphate Levels?

When arranging an iron infusion after heavy periods, ask the service to write down the drug’s full name. “IV iron” covers several formulations. The name gives you a starting point for discussing the proposed dose, safety checks and what to report afterward.

What the trials compared

The two PHOSPHARE-IDA trials randomized 245 adults who could not tolerate or had not responded to oral iron. Most were women with gynecological blood loss; reduced kidney function was excluded.¹

Ferric derisomaltose, then called iron isomaltoside, was given as 1,000 mg once. Ferric carboxymaltose was given as 750 mg twice, a week apart.¹

Those unequal total doses and schedules matter when interpreting the comparison.¹ Ask how the proposed course matches the studied regimen before applying a percentage to your own treatment.

A blood-test result, not a fracture rate

The primary outcome was phosphate below 2.0 mg/dL at any point through day 35. Rates were 7.9% versus 75.0% in one trial and 8.1% versus 73.7% in the other, with derisomaltose first in each comparison.¹

The studies did not measure clinical outcomes such as fractures, and follow-up ended before all biochemical effects could be tracked to resolution. Pharmacosmos, the derisomaltose manufacturer, sponsored them.¹

These percentages describe crossing a laboratory threshold. Keep them separate from the question of how often a person develops symptoms or a bone complication. Ask the clinician to explain what a low result would mean for your care.

What the current carboxymaltose warning requires

The US carboxymaltose label, revised in August 2026, carries a boxed warning about severe, prolonged low phosphate, including hospitalization, softened bones and fractures. Cases have occurred despite normal baseline phosphate and no apparent risk factors.²

It calls for correcting low phosphate before treatment, monitoring people at risk for chronically low phosphate, and checking phosphate before a repeat course in at-risk patients or anyone receiving another course within three months.²

Report fatigue, muscle weakness or pain, and bone or joint pain to the treating team.² Before leaving, get a contact number and a date for any planned tests. Tell the team about previous infusions, including the name and dates if you have them.

Put the formulation inside the whole treatment plan

The Monoferric label also warns about serious allergic reactions and requires observation for at least 30 minutes after its infusion, until clinically stable.³ A lower phosphate rate does not remove the need for an infusion safety plan.

Ask why this product was selected, how anemia and iron stores will be reviewed, and what treatment is proposed for the bleeding. Our oral-versus-IV iron guide and infusion appointment guide cover those discussions.

Period, Handled includes “The Iron Question” and “The Visit Script.” Use them to organize your iron results, bleeding history and the effect on daily life for that review. See the book.